KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Account Payables (2017 - 2025)

Pacira BioSciences has reported Change in Account Payables over the past 11 years, most recently at -$2.9 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$2.9 million for Q4 2025, down 801.23% from a year ago — trailing twelve months through Dec 2025 was -$5.6 million (down 281.52% YoY), and the annual figure for FY2025 was -$5.6 million, down 281.52%.
  • Change in Account Payables for Q4 2025 was -$2.9 million at Pacira BioSciences, up from -$12.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for PCRX hit a ceiling of $9.7 million in Q2 2024 and a floor of -$12.0 million in Q3 2025.
  • Median Change in Account Payables over the past 5 years was -$451000.0 (2022), compared with a mean of -$279400.0.
  • Biggest five-year swings in Change in Account Payables: surged 932.94% in 2023 and later tumbled 1985.87% in 2025.
  • Pacira BioSciences' Change in Account Payables stood at -$9.4 million in 2021, then surged by 116.86% to $1.6 million in 2022, then crashed by 167.38% to -$1.1 million in 2023, then surged by 69.68% to -$325000.0 in 2024, then plummeted by 801.23% to -$2.9 million in 2025.
  • The last three reported values for Change in Account Payables were -$2.9 million (Q4 2025), -$12.0 million (Q3 2025), and $6.9 million (Q2 2025) per Business Quant data.